NOV 28, 2016 11:07 AM PST

Cancer Drug May be Repurposed to Treat Muscular Dystrophy

WRITTEN BY: Xuan Pham
A cancer drug that’s approved for the treatment of kidney cancer may also be effective against a form of muscular dystrophy.
 

Sunitinib is a small-molecule drug that inhibits receptor tyrosine kinases (RTK). It was approved by the FDA for the treatment of renal cell carcinoma and a form of gastrointestinal tumor in 2006. Now, researchers at the King’s College London say the mechanism behind this drug may also act to improve muscle strength in patients with facioscapulohumeral dystrophy (FSHD).
 
FSHD is a genetically inherited form of muscular dystrophy that primarily affects the muscles around the face, shoulders, and upper arms. Patients with this condition experience progressive muscle wasting that starts in early childhood. The muscle weakness can severely impair mobility, speaking, and even breathing.
 
"Muscle dystrophies are an untreatable collection of diseases that result in progressive loss of mobility and often premature death, and affect millions of people worldwide,” said Robert Knight, Principal Investigator at the Division of Craniofacial Development and Stem Cell Biology at King’s College London’s Dental Institute, and the study’s co-lead author.
 
In studying muscle biology, researchers noted that a receptor tyrosine kinase Rearranged during transfection (RET) seemed to be upregulated in muscle stem cells that express the DUX4 protein. In FSHD, the genomic region controlling DUX4 appears to be abnormally activated (due to hypomethylation). This, in turn, overstimulates the production and activity of DUX4, which seems to contribute to the muscle weakness characteristic of FSHD.
 
Could an RTK inhibitor reverse this effect? This was the researcher’s main hypothesis, and they tested it first by confirming that overexpression of DUX4 in mice led to upregulation of RET. Furthermore, administration of sunitinib, an RTK inhibitor, suppressed RET activity and reduced damage to muscle cells.
 

“Specifically, blocking DUX4-mediated RET signaling increases myogenic differentiation, giving further insight into the molecular pathology of DUX4 and highlighting RET signaling as potential drug target," the authors explain.
 
The drug shows promise in improving muscle strength for patients afflicted with FSHD. And since the drug is already approved, repurposing it for the treatment of FSHD may take much less time, assuming further studies also find the same promising results.
 
“The discovery that an approved anticancer treatment may prove useful for enhancing the ability of stem cells to repair muscle in a type of muscle dystrophy affecting face and shoulder muscles offers a new route for putative therapies for many patients,” said Knight.

Additional sources: King's College London press release, MNT
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
MAR 16, 2021
Cancer
Does exposure to propylparaben during preganancy increase risk of breast cancer?
MAR 16, 2021
Does exposure to propylparaben during preganancy increase risk of breast cancer?
A concerning new study suggests that exposure during pregnancy to low doses of a common chemical preservative called pro ...
APR 17, 2021
Drug Discovery & Development
Facebook AI May Speed up Cancer Drug Discovery
APR 17, 2021
Facebook AI May Speed up Cancer Drug Discovery
Facebook has claimed that its new artificial intelligence, known as 'Compositional Perturbation Autoencoder' (CP ...
MAY 05, 2021
Immunology
Novel 3D Bio-printed Leukemia Model Shows Potential for Treatment Testing Platform
MAY 05, 2021
Novel 3D Bio-printed Leukemia Model Shows Potential for Treatment Testing Platform
Three-dimensional (3D) printing has become a common technique over the past two decades. Now, the technique has been ado ...
MAY 10, 2021
Cell & Molecular Biology
Getting RNA-Based Medicine Past the Blood-Brain Barrier
MAY 10, 2021
Getting RNA-Based Medicine Past the Blood-Brain Barrier
RNA molecules serve several functions, one of which is to help the cell generate proteins from active genes. It also may ...
MAY 16, 2021
Cancer
Can you guess which drug is both antiviral and immunotherapeutic?
MAY 16, 2021
Can you guess which drug is both antiviral and immunotherapeutic?
Hepatitis B virus (HBV) is the most common cause of liver cancer in the world, resulting in approximately 880,000 deaths ...
MAY 19, 2021
Cancer
How does environmental quality affect prostate cancer aggressiveness?
MAY 19, 2021
How does environmental quality affect prostate cancer aggressiveness?
A study from researchers at the University of Illinois Chicago investigates the link between environmental quality and p ...
Loading Comments...